why choose us

First received: May 11, 2023

Clinical Trial: Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Recurrent Vulvar Cancer

Study Type: INTERVENTIONAL


Official Title: Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (A Multicenter, Singl

Brief Summary: Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.

Read more